The city of Charlotte, North Carolina, currently has 12 active clinical trials seeking participants for Arthritis research studies.
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis
Recruiting
The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in biologic-experienced participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Joint and Muscle Research Institute, Charlotte, North Carolina
Conditions: Arthritis, Psoriatic
A Long-term Extension Study of Ustekinumab in Pediatric Participants
Recruiting
The purpose of this study is to collect long-term safety data of subcutaneous (SC) ustekinumab
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
03/28/2025
Locations: Levine Childrens at Atrium Health, Charlotte, North Carolina
Conditions: Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
Recruiting
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/21/2025
Locations: Arthrosi Investigative Site (625), Charlotte, North Carolina
Conditions: Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Recruiting
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how safe and effective upadacitinib is in treating RA when compared to adalimumab in adult participants with inadequate response or intolerance to one TNF-inhibitor who are on a stable dose of methotrexate (MTX). Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for the treatment of RA. This study is doubl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Joint And Muscle Research Institute /ID# 275128, Charlotte, North Carolina
Conditions: Rheumatoid Arthritis
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
Recruiting
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA based on their previous experience with specific treatments. The participants will be treated with either zasocitinib, or placebo. Participants will be in the study for up to 60 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: DJL Clinical Research | Charlotte, NC, Charlotte, North Carolina
Conditions: Psoriatic Arthritis
A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis
Recruiting
This is a parallel group, Phase 2, randomized, double-blind, placebo controlled, 5-arm, international, multicenter, 12-week proof of concept, dose finding study. It is designed to assess efficacy and safety of treatment with SAR441566 for 12 weeks. It will be conducted in male and female adult participants with moderate-to-severe rheumatoid arthritis (RA) not adequately controlled on methotrexate (MTX) and biologic/targeted synthetic disease modifying anti-rheumatic drug (DMARD) naive. Study tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Arthritis and Osteoporosis Consultants of the Carolinas- Site Number : 8400012, Charlotte, North Carolina
Conditions: Rheumatoid Arthritis
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
Recruiting
An open label phase 3 study
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Sunpharma site no 34, Charlotte, North Carolina
Conditions: Psoriatic Arthritis
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
Recruiting
Juvenile Idiopathic Arthritis (JIA) is the most common type of arthritis that affects children. The term "idiopathic" means "of unknown origin". It is a chronic (long-lasting) disease that causes swelling, warmth, and pain of one or more small joints. Systemic JIA ia a rare and serious form of JIA. Systemic" means it may affect not only the joints but other parts of the body, including the liver, lungs and heart. sJIA is more severe and can be more challenging to diagnose and treat than other ty... Read More
Gender:
ALL
Ages:
Between 1 year and 17 years
Trial Updated:
02/19/2025
Locations: Levine Children's Hospital /ID# 253491, Charlotte, North Carolina
Conditions: Juvenile Idiopathic Arthritis
Clinical Outcomes Study of the Nexel Total Elbow
Recruiting
The objectives of the study are to confirm safety and performance of the Zimmer Nexel Total Elbow when used in primary or revision total elbow replacement.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: OrthoCarolina Research Institute, Charlotte, North Carolina
Conditions: Elbow Joint Destruction, Post-traumatic Lesions, Ankylosed Joints, Advanced Rheumatoid Arthritis, Joint Instability or Loss of Motion, Acute Comminuted Articular Fracture of Elbow Joint Surfaces, Bone Loss Contributing to Elbow Instability, Bilateral Ankylosis From Causes Other Than Active Sepsis, Post-traumatic Arthritis, Degenerative Arthritis
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
Recruiting
This Phase 2b, multicenter, double-blind, placebo-controlled, randomized withdrawal study is designed to assess the efficacy and safety of IMVT-1402 in adult participants with active, difficult-to-treat, anti-citrullinated protein autoantibody (ACPA) positive rheumatoid arthritis (RA). The primary objective is to evaluate the effects of IMVT-1402 compared to placebo, as measured by the American College of Rheumatology 20% (ACR20) response.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2025
Locations: Site Number - 1004, Charlotte, North Carolina
Conditions: Rheumatoid Arthritis
Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants with Rheumatoid Arthritis with Inadequate Response or Intolerance to a DMARD Starting a New BDMARD or TsDMARD Treatment +/- CsDMARD
Recruiting
The primary goal of this study is to assess a cfDNA-based blood test using genetic, transcriptomic and/or epigenetic information to help doctors predict the best treatment options for rheumatoid arthritis (RA) patients with inadequate response or intolerance to previous therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, North Carolina
Conditions: Rheumatoid Arthritis
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)
Recruiting
The main objective of the study is to evaluate the safety, performance and clinical benefits of the Persona implant and its instrumentation in primary total knee arthroplasty
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/07/2024
Locations: OrthoCarolina Research Institute, Inc., Charlotte, North Carolina
Conditions: Knee Pain Chronic, Osteoarthritis, Knee, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Varus Deformity, Valgus Deformity, Flexion Deformity of Knee, Avascular Necrosis